FASLG and cancer: To test the effects of CD95L/BV6/FLIPin versus CD95L/BV6 co-treatment and CD95L/BV6/zVAD-fmk/FLIPin versus CD95L/BV6/zVAD-fmk co-treatment on non-cancer cells, we used day 6 activated primary T cells from healthy donors (Figure 8; Supplementary Figure S5).